These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9923094)

  • 1. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie.
    Poynard T; Moussalli J; Ratziu V; Thevenot T; Regimbeau C; Opolon P; Horsmans Y; Brenard R; Closon M; Fevery J; Hautekeete M
    Acta Gastroenterol Belg; 1998; 61(4):431-7. PubMed ID: 9923094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of hepatitis C virus-related cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B220-4. PubMed ID: 12180292
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C.
    Khokhar N; Niazi TK; Qureshi MO
    J Coll Physicians Surg Pak; 2013 Oct; 23(10):699-702. PubMed ID: 24112253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin.
    Vukotic R; Gramenzi A; Vitale G; Cursaro C; Serra C; Biselli M; Scuteri A; Andreone P; Bernardi M
    Liver Int; 2008 Mar; 28(3):407-11. PubMed ID: 17900241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL; Guindi M; Tomlinson G; Heathcote J
    Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of chronic hepatitis C].
    Rókusz L
    Orv Hetil; 2004 Aug; 145(32):1649-53. PubMed ID: 15384863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials.
    Brok J; Gluud LL; Gluud C
    Arch Intern Med; 2005 Oct; 165(19):2206-12. PubMed ID: 16246984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
    Karpińska E; Wawrzynowicz-Syczewska M; Jurczyk K; Morańska I; Urbanowicz W; Boroń-Kaczmarska A
    Wiad Lek; 2005; 58(11-12):616-21. PubMed ID: 16594470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
    Yamamoto T; Tanaka S; Uenishi T; Kanazawa A; Kubo S; Hirohashi K
    Osaka City Med J; 2014 Dec; 60(2):95-100. PubMed ID: 25803885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
    Main J
    J Hepatol; 1995; 23 Suppl 2():32-5; discussion 35-6. PubMed ID: 8720292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features of antiviral therapy in 12 patients with hepatitis C virus-related cirrhosis after splenectomy].
    Ma LN; He ZM; Hua W; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Aug; 21(8):594-8. PubMed ID: 24119739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis C virus infection after liver transplantation.
    Agarwal K; Barnabas A
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S349-54. PubMed ID: 24091115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials.
    Cheng SJ; Bonis PA; Lau J; Pham NQ; Wong JB
    Hepatology; 2001 Jan; 33(1):231-40. PubMed ID: 11124841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.